anti-BCMA CAR T-cell therapy engineered to express anti-IL6 scFv and IL1RA (Celledit)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-BCMA CAR T-cell therapy engineered to express anti-IL6 scFv and IL1RA (Celledit)
Drug Alias NameBCMA.CAR T/IL6/IL1 (Celledit)BCMA.CART/IL6/IL1 (Celledit)anti-BCMA CAR T-cell therapy that produce anti-IL6 scFv and IL1RA (Celledit)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionIL-6 receptor antagonistsInterleukin-1 receptor antagonistsTumor necrosis factor ligand superfamily member 13 modulators
TargetsIL-6 receptorTumor necrosis factor ligand superfamily member 13Interleukin-1 receptor
Therapy Area/IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesCelledit Llc
China Registration ClassN/A

Develop Information

Active CompaniesCelledit Llc
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A